HDAC9 and urinary bladder carcinoma: However, others have found a seemingly contradictory impact of histone deacetylase (HDAC) inhibitors in bladder cancer, showing a correlation between HDAC inhibition, increased XPC expression and higher cisplatin-induced activation of the pro-apoptotic protein, caspase 3 (139).